Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals OyAnnouncement

03/02/2026 16:00

Faron Pharmaceuticals Ltd | Company announcement | February 03, 2026 at
18:00:00 EET

Capitalised terms used in this announcement have the meanings given to them in
the announcement made at 9.00 a.m. EET 3 February 2026 regarding the
amortisation payment and approval of share subscriptions based on special
rights, unless the context provides otherwise.

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company developing novel immunotherapies,
has, as announced earlier today on 3 February 2026, approved the exercise of
909,517 Special Rights entitling to 909,517 new Shares, for an aggregate
subscription price of EUR 1,549,998.87.

In total 909,517 new shares in the Company have today on 3 February 2026 been
registered in the Finnish Trade Register. The shares rank pari passu in all
respects with the existing shares of the Company. Following the issuance, the
aggregate number of ordinary shares in the Company is 119,472,660. Shares held
in treasury by the Company do not confer a right to dividends or other
shareholder rights. Following the registration, the Company continues to have
3,688,699 shares in treasury and therefore, the total number of voting rights
in Faron is 115,783,961 (the “Number of Shares and Votes”). This figure may be
used by shareholders as the denominator for the calculations by which they
will determine whether they are required to notify an interest in, or a change
to their interest in, the Number of Shares and Votes of the Company.

Trading in the new shares is expected to commence on First North and AIM on or
around 5 February 2026.

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             | +358 50 553 9535 / +44 7 469 766 223 |
|                                     | kare.laukkanen@irpartners.fi         |
| Kare Laukkanen                      |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   | +1 847 791-8085                      |
| (Media)                             | alyssa.paldo@finnpartners.com        |
| Alyssa Paldo                        |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        | +44 (0) 207 213 0880                 |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    | +358 (0)40 555 4727                  |
| (Certified Adviser on Nasdaq First  | +358 (0)50 553 8990                  |
| North)                              |                                      |
| Juha Karttunen                      |                                      |
| Jukka Järvelä                       |                                      |
+-------------------------------------+--------------------------------------+

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company’s lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical trials as
a potential therapy for patients with hematological cancers in combination
with other standard treatments. Further information is available
at www.faron.com. (http://www.faron.com/)